Skip to main content

Advertisement

Table 1 Baseline demographics and clinical characteristics for the pneumococcal vaccination population

From: Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Characteristic Pneumococcal vaccine population (N = 125)
Age
 Mean (SD), years 45.7 (13.8)
Sex
 Women, n (%) 107 (85.6)
 Men, n (%) 18 (14.4)
Race
 White, n (%) 124 (99.2)
 Black/African American, n (%) 1 (0.8)
Region
 South America, n (%) 105 (84.0)
 North America, n (%) 20 (16.0)
Weight
 Mean (SD), kg 68.9 (17.9)
Duration of abatacept exposure during main study
 Mean (SD), months 26.4 (2.5)
Tender joint count/28
 Mean (SD) 20.4 (16.7)
Swollen joint count/28
 Mean (SD) 13.9 (11.5)
Patient pain
 100-mm VAS, mean (SD) 51.0 (29.4)
HAQ-DI
 Mean (SD) 1.4 (0.8)
C-reactive protein
 Mean (SD), mg/dL 1.8 (2.5)
Patient global assessment
 100-mm VAS, mean (SD) 43.9 (31.9)
Physician global assessment
 100-mm VAS, mean (SD) 48.5 (26.3)
DAS28 (C-reactive protein)
 Mean (SD) 5.0 (1.9)
Concomitant methotrexate
n (%) 115 (92.0)
  1. DAS28 Disease Activity Score 28, HAQ-DI Health Assessment Questionnaire-Disability Index, SD standard deviation, VAS visual analog scale